{"title":"术中氯胺酮/艾氯胺酮预防术后谵妄的疗效:系统回顾和荟萃分析。","authors":"Chengchuan Chen, Na Zhou, Jixin Hou","doi":"10.1177/20451253251339378","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Postoperative delirium (POD) is associated with higher risks of postoperative complications and mortality (2- to 3-fold increase). Studies investigating the effect of intraoperative ketamine on POD risk have yielded conflicting results. This study aimed to assess the effects of intraoperative ketamine and its more potent version, esketamine, on POD.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Objective: </strong>To evaluate the effect of intraoperative ketamine/esketamine on the incidence of POD.</p><p><strong>Methods: </strong>We adhered to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, and searched the PubMed, Embase, Medline (Ovid), Cochrane, Scopus, and Web of Science databases for the MeSH terms \"ketamine\" and \"emergence delirium\" from database inception to July 10, 2024. The primary outcome was POD incidence following general anesthesia. Data were analyzed using a common effects model, with between-study heterogeneity tested using the <i>I</i> <sup>2</sup> statistic, and relative risk (RR) with 95% confidence intervals (CIs) for dichotomous data was used as the effect measure.</p><p><strong>Results: </strong>A total of 18 studies with a total of 1571 participants met eligibility criteria. A meta-analysis of all studies suggests that the intraoperative use of ketamine/esketamine may reduce the incidence of POD (RR = 0.71, 95% CI: 0.56, 0.90, <i>p</i> < 0.01). In the drug subgroup, esketamine demonstrated enhanced efficacy in preventing POD compared to ketamine (RR = 0.59, 95% CI: 0.38, 0.90, <i>p</i> = 0.02). In addition, subanesthetic doses of ketamine/esketamine (⩽0.5 mg/kg) contributed to POD prevention (RR = 0.52, 95% CI: 0.34, 0.79, <i>p</i> < 0.01), whereas higher doses (>0.5 mg/kg) showed no statistically significant effect (RR = 0.89, 95% CI: 0.66, 1.21, <i>p</i> = 0.46). Further analysis revealed additional benefits of ketamine/esketamine in reducing POD incidence in cardiac surgery (RR = 0.46, 95% CI: 0.31, 0.68, <i>p</i> < 0.01), in the elderly (RR = 0.68, 95% CI: 0.52, 0.91, <i>p</i> < 0.01), and in the first 24 h post-surgery (RR = 0.52, 95% CI: 0.29, 0.94, <i>p</i> = 0.03).</p><p><strong>Conclusion: </strong>Our findings suggest that perioperative administration of ketamine/esketamine had a protective effect against the incidence of POD, with esketamine demonstrating superior efficacy compared to ketamine. The treatment effect exhibited a dose-response relationship, with subanesthetic doses showing greater efficacy. Furthermore, ketamine/esketamine may offer additional benefits for patients with specific risk factors.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251339378"},"PeriodicalIF":4.0000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450268/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy of intraoperative ketamine/esketamine in the prevention of postoperative delirium: a systematic review and meta-analysis.\",\"authors\":\"Chengchuan Chen, Na Zhou, Jixin Hou\",\"doi\":\"10.1177/20451253251339378\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Postoperative delirium (POD) is associated with higher risks of postoperative complications and mortality (2- to 3-fold increase). Studies investigating the effect of intraoperative ketamine on POD risk have yielded conflicting results. This study aimed to assess the effects of intraoperative ketamine and its more potent version, esketamine, on POD.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Objective: </strong>To evaluate the effect of intraoperative ketamine/esketamine on the incidence of POD.</p><p><strong>Methods: </strong>We adhered to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, and searched the PubMed, Embase, Medline (Ovid), Cochrane, Scopus, and Web of Science databases for the MeSH terms \\\"ketamine\\\" and \\\"emergence delirium\\\" from database inception to July 10, 2024. The primary outcome was POD incidence following general anesthesia. Data were analyzed using a common effects model, with between-study heterogeneity tested using the <i>I</i> <sup>2</sup> statistic, and relative risk (RR) with 95% confidence intervals (CIs) for dichotomous data was used as the effect measure.</p><p><strong>Results: </strong>A total of 18 studies with a total of 1571 participants met eligibility criteria. A meta-analysis of all studies suggests that the intraoperative use of ketamine/esketamine may reduce the incidence of POD (RR = 0.71, 95% CI: 0.56, 0.90, <i>p</i> < 0.01). In the drug subgroup, esketamine demonstrated enhanced efficacy in preventing POD compared to ketamine (RR = 0.59, 95% CI: 0.38, 0.90, <i>p</i> = 0.02). In addition, subanesthetic doses of ketamine/esketamine (⩽0.5 mg/kg) contributed to POD prevention (RR = 0.52, 95% CI: 0.34, 0.79, <i>p</i> < 0.01), whereas higher doses (>0.5 mg/kg) showed no statistically significant effect (RR = 0.89, 95% CI: 0.66, 1.21, <i>p</i> = 0.46). Further analysis revealed additional benefits of ketamine/esketamine in reducing POD incidence in cardiac surgery (RR = 0.46, 95% CI: 0.31, 0.68, <i>p</i> < 0.01), in the elderly (RR = 0.68, 95% CI: 0.52, 0.91, <i>p</i> < 0.01), and in the first 24 h post-surgery (RR = 0.52, 95% CI: 0.29, 0.94, <i>p</i> = 0.03).</p><p><strong>Conclusion: </strong>Our findings suggest that perioperative administration of ketamine/esketamine had a protective effect against the incidence of POD, with esketamine demonstrating superior efficacy compared to ketamine. The treatment effect exhibited a dose-response relationship, with subanesthetic doses showing greater efficacy. Furthermore, ketamine/esketamine may offer additional benefits for patients with specific risk factors.</p>\",\"PeriodicalId\":23127,\"journal\":{\"name\":\"Therapeutic Advances in Psychopharmacology\",\"volume\":\"15 \",\"pages\":\"20451253251339378\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450268/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20451253251339378\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20451253251339378","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
背景:术后谵妄(POD)与较高的术后并发症和死亡率相关(增加2- 3倍)。调查术中氯胺酮对POD风险影响的研究得出了相互矛盾的结果。本研究旨在评估术中氯胺酮及其更有效的艾氯胺酮对POD的影响。设计:系统回顾和荟萃分析。目的:评价术中氯胺酮/艾氯胺酮对POD发生率的影响。方法:我们遵循PRISMA (Preferred Reporting Items for Systematic Reviews and meta - analysis)指南,检索PubMed、Embase、Medline (Ovid)、Cochrane、Scopus和Web of Science数据库,从数据库建立到2024年7月10日,检索MeSH术语“氯胺酮”和“出现性谵妄”。主要观察指标是全麻后POD的发生率。采用通用效应模型对数据进行分析,采用i2统计量检验研究间异质性,采用二分类数据95%置信区间的相对危险度(RR)作为效应测度。结果:共有18项研究共1571名受试者符合入选标准。所有研究的荟萃分析表明,术中使用氯胺酮/艾氯胺酮可降低POD的发生率(RR = 0.71, 95% CI: 0.56, 0.90, p = 0.02)。此外,亚麻醉剂量氯胺酮/艾氯胺酮(≥0.5 mg/kg)有助于预防POD (RR = 0.52, 95% CI: 0.34, 0.79, p 0.5 mg/kg),但效果无统计学意义(RR = 0.89, 95% CI: 0.66, 1.21, p = 0.46)。进一步分析显示氯胺酮/艾氯胺酮在降低心脏手术中POD发病率方面有额外的益处(RR = 0.46, 95% CI: 0.31, 0.68, p p p = 0.03)。结论:我们的研究结果提示围手术期给予氯胺酮/艾氯胺酮对POD的发生率有保护作用,艾氯胺酮的疗效优于氯胺酮。治疗效果表现出剂量-反应关系,亚麻醉剂量表现出更大的疗效。此外,氯胺酮/艾氯胺酮可能为具有特定危险因素的患者提供额外的益处。
Efficacy of intraoperative ketamine/esketamine in the prevention of postoperative delirium: a systematic review and meta-analysis.
Background: Postoperative delirium (POD) is associated with higher risks of postoperative complications and mortality (2- to 3-fold increase). Studies investigating the effect of intraoperative ketamine on POD risk have yielded conflicting results. This study aimed to assess the effects of intraoperative ketamine and its more potent version, esketamine, on POD.
Design: Systematic review and meta-analysis.
Objective: To evaluate the effect of intraoperative ketamine/esketamine on the incidence of POD.
Methods: We adhered to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, and searched the PubMed, Embase, Medline (Ovid), Cochrane, Scopus, and Web of Science databases for the MeSH terms "ketamine" and "emergence delirium" from database inception to July 10, 2024. The primary outcome was POD incidence following general anesthesia. Data were analyzed using a common effects model, with between-study heterogeneity tested using the I2 statistic, and relative risk (RR) with 95% confidence intervals (CIs) for dichotomous data was used as the effect measure.
Results: A total of 18 studies with a total of 1571 participants met eligibility criteria. A meta-analysis of all studies suggests that the intraoperative use of ketamine/esketamine may reduce the incidence of POD (RR = 0.71, 95% CI: 0.56, 0.90, p < 0.01). In the drug subgroup, esketamine demonstrated enhanced efficacy in preventing POD compared to ketamine (RR = 0.59, 95% CI: 0.38, 0.90, p = 0.02). In addition, subanesthetic doses of ketamine/esketamine (⩽0.5 mg/kg) contributed to POD prevention (RR = 0.52, 95% CI: 0.34, 0.79, p < 0.01), whereas higher doses (>0.5 mg/kg) showed no statistically significant effect (RR = 0.89, 95% CI: 0.66, 1.21, p = 0.46). Further analysis revealed additional benefits of ketamine/esketamine in reducing POD incidence in cardiac surgery (RR = 0.46, 95% CI: 0.31, 0.68, p < 0.01), in the elderly (RR = 0.68, 95% CI: 0.52, 0.91, p < 0.01), and in the first 24 h post-surgery (RR = 0.52, 95% CI: 0.29, 0.94, p = 0.03).
Conclusion: Our findings suggest that perioperative administration of ketamine/esketamine had a protective effect against the incidence of POD, with esketamine demonstrating superior efficacy compared to ketamine. The treatment effect exhibited a dose-response relationship, with subanesthetic doses showing greater efficacy. Furthermore, ketamine/esketamine may offer additional benefits for patients with specific risk factors.
期刊介绍:
Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area.